Safety monitoring of COVID-19 vaccine booster doses among adults — U.S. September 22, 2021–February 6, 2022

Hause, Anne M.; Baggs, James; Marquez, Paige; Myers, Tanya R.; Su, John R.; Blanc, Phillip G.; Baumblatt, Jane A. Gwira; Woo, Emily Jane; Gee, Julianne; Shimabukuro, Tom T.; Shay, David K.

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Safety monitoring of COVID-19 vaccine booster doses among adults — U.S. September 22, 2021–February 6, 2022

February 11, 2022
By Hause, Anne M. ; Baggs, James ; Marquez, Paige ; ...
Series: MMWR; v. 71, ER, 2/11/22

[PDF-451.30 KB]

English

Details Supporting Files You May Also Like

Details:

Personal Author:

Hause, Anne M. ; Baggs, James ; Marquez, Paige ; Myers, Tanya R. ; Su, John R. ; ... More +

Hause, Anne M. ; Baggs, James ; Marquez, Paige ; Myers, Tanya R. ; Su, John R. ; Blanc, Phillip G. ; Baumblatt, Jane A. Gwira ; Woo, Emily Jane ; Gee, Julianne ; Shimabukuro, Tom T. ; Shay, David K. Less -
Corporate Authors:

CDC COVID-19 Emergency Response Team ; U.S. Food and Drug Administration

CDC COVID-19 Emergency Response Team ; U.S. Food and Drug Administration Less -
Description:

What is already known about this topic? In preauthorization trials, adverse reactions were reported less frequently following a homologous COVID-19 mRNA vaccine booster dose than after receipt of the second primary dose.

What is added by this report? Review of Surveillance data found that local and systemic reactions were less frequent after a homologous COVID-19 mRNA vaccine booster dose than after the second primary vaccine dose. Myocarditis was rarely reported following an mRNA vaccine booster dose.

What are the implications for public health practice? All persons aged ≥12 years should receive a COVID-19 booster dose. Vaccination providers should educate patients that local and systemic reactions are expected following a homologous COVID-19 mRNA vaccine booster; however, these reactions are less common than those following the second primary series dose.

Suggested citation for this article: Hause AM, Baggs J, Marquez P, et al. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults — U.S. September 22, 2021–February 6, 2022. MMWR Morb Mortal Wkly Rep. ePub: 11 February 2022.

mm7107e1.htm?s_cid=mm7107e1_w

mm7107e1-H.pdf
Subjects:

[+]

2019-nCoV Vaccine MRNA-1273 BNT162 Vaccine CoronaVirus Infections/Prevention & Control COVID-19 Vaccines COVID-19/Prevention & Control Immunization, Secondary Vaccination
Series:

MMWR; v. 71, ER, 2/11/22
Document Type:

Journal Article
Name as Subject:

Moderna Covid-19 Vaccine ; Pfizer-BioNTech COVID-19 Vaccine ; Moderna Covid-19 Vaccine ; Pfizer-BioNTech COVID-19 Vaccine

Moderna Covid-19 Vaccine ; Pfizer-BioNTech COVID-19 Vaccine ; Moderna Covid-19 Vaccine ; Pfizer-BioNTech COVID-19 Vaccine Less -
Place as Subject:

U.S.
Pages in Document:

6 numbered pages
Volume:

71
Collection(s):

Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha256:60d6d4fcff2c7d3a5c1333fcc81823e5bc64087c2f95a4fe51133fdb26611aa5
Download URL:

https://stacks.cdc.gov/view/cdc/114421/cdc_114421_DS1.pdf
File Type:

mm7107e1.htm

htm

More +